Dato Dr Kim Tan PhD

Chairman of SpringHill Management, a private fund management company specialising in biotech and social venture capital investments. He is a partner and advisor to a number of impact funds including Springhill Equity Partners (US), Inqo (SA), Novastar Ventures (Kenya), Truestone Impact Investment Fund (UK) and Garden Impact Investment (Singapore). He is the co-founder of the Transformational Business Network and is on the advisory boards of the John Templeton Foundation, Johnson & Johnson Citizenship Trust and PovertyCure. He is a board member of the Centre for Enterprise, Markets & Ethics (Oxford) and the APEC Life Science Innovation Forum. He was the founder chairman of the Nilai Cancer Hospital (Malaysia) and a board member of the Saracens Rugby Club (UK). He is a Pro-Chancellor of the University of Surrey (UK), the inventor of sheep monoclonal antibodies and a Fellow of the Royal Society of Medicine (UK).